- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05857241
Therapeutic Fasting and Immune Aging (JÛVENILE)
Therapeutic Fasting and Immune Aging: A Pilot Study of Tolerance
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Baptiste GRAMONT, MD
- Phone Number: +33 (0)0477829641
- Email: Baptiste.Gramont@chu-st-etienne.fr
Study Contact Backup
- Name: Florence RANCON, CRA
- Email: florence.rancon@chu-st-etienne.fr
Study Locations
-
-
-
Le Chambon-Feugerolles, France, 42500
- EHPAD Claudinon
-
Contact:
- Romain JUGAND, MD
-
Principal Investigator:
- Romain JUGAND, MD
-
Malataverne, France, 43200
- EHPAD Les Cèdres Malataverne
-
Contact:
- Aurélie BUISSON, MD
-
Principal Investigator:
- Aurélie BUISSON
-
Saint-Etienne, France, 42055
- CHU DE SAINT-ETIENNE
-
Sub-Investigator:
- Martin KILLIAN, MD
-
Contact:
- Baptiste GRAMONT, MD
-
Principal Investigator:
- Baptiste GRAMONT, MD
-
Saint-Just-Saint-Rambert, France, 42170
- EHPAD La M.R.L
-
Contact:
- Anne PAVY, MD
-
Principal Investigator:
- Anne PAVY, MD
-
Saint-Étienne, France
- EHPAD de la Talaudière, la Rivière, la Croix de l'Horme
-
Contact:
- Thomas CELARIER, PhD
-
Principal Investigator:
- Thomas CELARIER
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria :
- Patient affiliated or entitled to a social security scheme
- Residing in a Long-Term Care Unit (LTCU) or a Facility for the Elderly Dependent (EHPAD)
- A person deemed a priori, by the geriatrician member of the monitoring committee, to be capable of following the dietary recommendations required for the study.
- A person deemed a priori, by the clinician in charge, to be able to follow the dietary recommendations required by the study.
- Patient who has received informed information about the study and has co-signed a consent to participate in the study with the investigator.
Exclusion Criteria :
- Inability and/or unwillingness to follow dietary recommendations and/or perform follow-up examinations required for the study
- Iso-resource group 1 or 2 according to the AGGIR grid
- BMI < 18.5 kg/m2 or recent weight loss > 5% in 1 month or recent weight loss > 10% in 6 months from previous weight
- Albuminemia < 30g/l
- All swallowing disorders requiring a specific diet.
- Influenza vaccination received prior to inclusion
- Episode of influenza or suspected influenza during the 2020-2021 season and prior to inclusion
- Any acute medical or surgical event less than 2 weeks prior to inclusion
- Presence of systemic inflammatory or autoimmune disease
- Presence of an innate or acquired immune deficiency (including taking immunosuppressive treatment)
- Presence of a chronic disease which, according to the physician, makes the follow-up of a "fasting diet" and/or the consumption of large amounts of liquids (cf. fasting diet modalities) risky (e.g. insulin-dependent or insulin-requiring diabetes, severe heart failure, severe kidney failure, active cancer, significant undernutrition...) or impossible (e.g. advanced neurodegenerative pathology).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fasting mimicking diet (FMD)
patients aged 65 and over, institutionalized in Long Term Care Units (USLD) or Establishments for the elderly (EHPAD).
|
D1 will correspond to a "pre-fasting" phase, with about 800 kcal of intake (approximately 40% of normal caloric intake) from a mono-nutrient diet (fruit, rice or potato according to the patient's preferences).
Then D2 and D3 will correspond to the days of actual fasting, with 200-350 kcal of intake (10-18% of normal caloric intake) in the form of 100 ml of broth or vegetable juice (with a teaspoon of linseed oil) three times a day, and vaccination will take place on D4, after returning to a normal diet. 2 to 3 liter of water or unsweetened drink per day is required.Laxatives (unsweetened) will be prescribed and can be taken as during the fasting period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rate of premature discontinuation of the fasting-mimicking diet
Time Frame: between Day 14 and Day 21
|
measurement of the rate of occurrence of a clinical event considered to require discontinuation of the fasting diet : The occurrence of a clinical event considered to require discontinuation of the fasting diet will be defined as the presence between D14 and D21 of at least one of the following conditions:
|
between Day 14 and Day 21
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
serious and non-serious adverse events reported
Time Frame: Between day 0 to day 42
|
Comparison of the nature and frequency of serious and non-serious adverse events reported from D0 to D13 (pre fasting diet phase), D14 to D16 (fasting diet phase) and D17 to D42 (post fasting diet phase)
|
Between day 0 to day 42
|
composite outcome: evolution of biological biochemic parameters
Time Frame: Day 0 to Day 42
|
Evolution of measurements of blood glucose, ketones, albumin, prealbumin and IGF-1 Unit of measure : ng/ml
|
Day 0 to Day 42
|
composite outcome: evolution of biological blood parameters
Time Frame: Day 0 to Day 42
|
Evolution of the measurement of the blood total lymphocyte count (CD4, CD8, CD19, naive, effectors, memories, regulators, etc.). Unit of measure : % |
Day 0 to Day 42
|
composite outcome: evolution biological inflammatory parameters
Time Frame: Day 0 to Day 42
|
Evolution of inflammatory markers (CRP, IL1, IL6, TNFalpha) Unit of measure : ng/ml
|
Day 0 to Day 42
|
Collaborators and Investigators
Investigators
- Principal Investigator: Baptiste GRAMONT, MD, Baptiste.Gramont@chu-st-etienne.fr
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 21CH028
- 2023-A00390-45 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diet, Healthy
-
University of ReadingActive, not recruitingDiet Modification | Diet, Healthy | Diet HabitUnited Kingdom
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
Washington State UniversityUnited States Department of Agriculture (USDA)Not yet recruitingHealth Behavior | Diet, Healthy | Diet HabitUnited States
-
University of HawaiiPennington Biomedical Research Center; United States Department of Agriculture...RecruitingDiet, HealthyUnited States
-
Harokopio UniversityRecruiting
-
Universitas Katolik Widya Mandala SurabayaNot yet recruitingDiet, HealthyIndonesia
-
Ohio State University Comprehensive Cancer CenterRecruitingHealthy DietUnited States
-
Purdue UniversityMushroom CouncilCompleted
-
University of PalermoCompleted
Clinical Trials on Fasting mimicking diet (FMD)
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Institut National de la Santé Et de la Recherche Médicale, France; Martin-Luther-Universität... and other collaboratorsUnknownBreast Cancer | Melanoma, MalignantItaly
-
Fondazione Valter LongoUniversity of Palermo; University of Calabria; Regione Calabria / Comune Varapodio and other collaboratorsRecruitingRisk Behavior | Obesity | OverweightItaly
-
Uniter OnlusUniversity of Rome Tor VergataCompletedObesity | Diet, Healthy | Olfaction DisordersItaly
-
Stephen FreedlandNational Cancer Institute (NCI)RecruitingProstate AdenocarcinomaUnited States
-
Technische Universität DresdenNot yet recruitingMyelodysplastic Syndromes
-
Ospedale Policlinico San MartinoActive, not recruiting
-
Leiden University Medical CenterRadboud University Medical Center; Health Holland; Dutch Kidney FoundationCompletedGlucose Metabolism Disorders | Kidney Diseases | Diabetes Mellitus | Diabetic Nephropathies | Albuminuria | Microalbuminuria | Type2 Diabetes Mellitus | Diabetic Nephropathy Type 2 | Diabetic Complications Renal | South AsianNetherlands
-
Indiana UniversityCompletedNon-small Cell Lung CancerUnited States
-
Leiden University Medical CenterHealth Holland; Dutch Diabetes Research Foundation; IFOM, The FIRC Institute... and other collaboratorsCompletedDiabetes Mellitus, Type 2Netherlands